Acarbose
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Acarbose: From Type 2 Diabetes to Classic Stiff Person Syndrome
One-Sentence Summary
Acarbose is an intestinal alpha-glucosidase inhibitor that lowers postprandial blood glucose, and it is marketed in the US as oral tablets. The TxGNN model predicts it may be effective for classic stiff person syndrome, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the supplied US license records; acarbose is an alpha-glucosidase inhibitor that lowers postprandial glucose (type 2 diabetes) |
| Predicted New Indication | Classic stiff person syndrome |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 17 (all listed licenses are ANDA generics) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Acarbose is known to inhibit intestinal alpha-glucosidase, which slows carbohydrate digestion and blunts the rise in blood glucose after meals.
Stiff person syndrome is an autoimmune neurological disorder, typically involving anti-GAD antibodies and disrupted GABAergic signalling. No plausible mechanistic link to alpha-glucosidase inhibition was found in the supplied data. The high score is most likely a knowledge-graph artifact, for example the known association between stiff person syndrome and diabetes.
The same pattern applies to the other high-scoring predictions, which are also L5 with no trials or literature:
- Focal stiff limb syndrome: a stiff person spectrum variant, same reasoning.
- Thiamine-responsive dysfunction syndrome: at most indirect glycemic control, with no effect on the underlying transporter defect.
- Opsismodysplasia: a rare skeletal dysplasia with no evident connection.
- Localized lipodystrophies (drug-induced, centrifugal, pressure-induced, idiopathic): no known effect of acarbose on adipose tissue.
- Pancreatic agenesis (rank 9): the only prediction with retrieved literature (L4), but the papers concern type 2 diabetes, insulin autoimmune syndrome and animal models rather than pancreatic agenesis itself. Insulin remains the required therapy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
17 licenses are recorded. All are tablets, and the main distinct ones are listed below. Approved indication text was not included in the supplied records.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA090912 | Acarbose | Tablet | Strides Pharma Science Limited |
| ANDA202271 | Acarbose | Tablet | Chartwell RX, LLC |
| ANDA202271 | Acarbose | Tablet | Bryant Ranch Prepack |
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found for acarbose in the supplied data.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score but no trials, no literature and no plausible mechanism linking alpha-glucosidase inhibition to stiff person syndrome. It is most likely a knowledge-graph artifact, so it does not justify further investment.
To proceed, the following is needed:
- A credible mechanistic hypothesis connecting acarbose to anti-GAD autoimmunity or GABAergic pathways
- Any preclinical or clinical signal specific to stiff person syndrome
- Package insert warnings, contraindications and approved indication text (the safety screening stage cannot proceed without them)
- Detailed mechanism of action data from DrugBank
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.